GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation
Advanced Science · 2025
DOI: 10.1002/advs.202504816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Ruiheng Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410000, P. R. China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, NIMA-Related Kinases, Inflammasomes. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Provincial Natural Science Foundation of Hunan in China, Shanghai Municipal Commission of Science and Technology.
Abstract (Originalsprache)
NLRP3 inflammasome is a multiple protein complex sensing exogenous or endogenous stimuli, and aberrant activation of the NLRP3 inflammasome is implicated in various inflammatory disorders. While numerous small‐molecule compounds targeting NLRP3 inflammasome activity have been developed, most have encountered limited success in clinical translation. Through screening of a kinase compound library, GSK461364 is identified as a potent and selective NLRP3 inflammasome inhibitor. Notably, GSK461364 confers significant protective effects in murine models of LPS‐induced endotoxemia and DSS‐induced colitis. Mechanistic study reveals that GSK461364 exerts its inhibitory effects via targeting Polo‐like Kinase 1(PLK1). Specifically, that PLK1‐mediated phosphorylation of NEK7, likely occurring at evolutionarily conserved serine residues (Ser221 and Ser260), is shown to enhance NEK7‐NLRP3 binding, a critical step for NLRP3 inflammasome assembly. These findings not only establish GSK461364 as a novel therapeutic candidate for NLRP3‐driven inflammatory diseases but also provide new insights into the regulatory mechanisms governing inflammasome activation through post‐translational modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410000, P. R. China.
- Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410000, P. R. China.
- Healthcare Security Department, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, 410000, P. R. China.
- Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, 201306, P. R. China.
- China National Pathogen Collection Center for Aquatic Animals, Shanghai Ocean University, Shanghai, 201306, P. R. China.
- Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, P. R. China.
ORCID-Profile: Kai Zhao
Förderung
- National Natural Science Foundation of China
- Provincial Natural Science Foundation of Hunan in China
- Shanghai Municipal Commission of Science and Technology
- Third xiangya hospital of Central South University
Zitieren
APA
Luo, R., Ma, M., Wang, D., Luo, L., Xu, X., Huang, L., Wang, F., Kuang, G., Liu, H., Ni, R., Li, X., Zhang, Q., Wang, S., & Zhao, K. (2025). GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation. Advanced Science. https://doi.org/10.1002/advs.202504816
Vancouver
Luo R, Ma M, Wang D, Luo L, Xu X, Huang L, et al. GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation. Advanced Science. 2025. doi:10.1002/advs.202504816
BibTeX
@article{Luo2025,
author = {Luo, Ruiheng and Ma, Mingliang and Wang, Dan and Luo, Ling and Xu, Xueming and Huang, Lingmin and Wang, Fupeng and Kuang, Guangyan and Liu, Huiqi and Ni, Rui and Li, Xin and Zhang, Qinghua and Wang, Shengfeng and Zhao, Kai},
title = {GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504816}
}
EUVIMED